Tectonic Therapeutic, Inc. (TECX): Among the Most Expensive Stocks Insiders Are Buying Recently
We recently compiled a list of the 11 Most Expensive Stocks Insiders Are Buying Recently. In this article, we are going to ...
Dual mechanisms found to guard mitochondria against fusion-related damage
Johns Hopkins University School of Medicine researchers have discovered a dual regulatory mechanism safeguarding ...
MIT Neuroscientists Discover a Tiny Brain Receptor That Could Transform Fragile X Treatment
MIT neuroscientists have made a breakthrough in treating fragile X syndrome by leveraging a novel neurotransmitter signaling ...
eLife1d
Structure-guided secretome analysis of gall-forming microbes offers insights into effector diversity and evolution
This study presents an important discovery regarding the diversity and evolution of gall-forming microbial effectors. Supported by convincing computational structural predictions and analyses, the ...
Tectonic Therapeutic to Participate in March Investor Conferences
Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the ...
Skye Bioscience to Present at TD Cowen Health Care Conference
A live and archived webcast will be accessible on Skye’s website.
Wells Fargo & Company Downgrades Septerna (NASDAQ:SEPN) to Equal Weight
Septerna (NASDAQ:SEPN – Get Free Report) was downgraded by equities researchers at Wells Fargo & Company from an “overweight” rating to an “equal weight” rating in a research note issued on Tuesday, ...
BioWorld3d
G-protein coupled receptor kinase is cystic fibrosis target
Cystic fibrosis is a life-threatening disease predominantly with respiratory symptoms. Most of the subjects with the disease harbor the F508del variant in the CFTR gene that causes the protein to ...
precisionmedicineonline4d
FDA Grants Priority Review to Chimerix for Dordaviprone in H3 K27M-Mutant Diffuse Glioma
In a Phase III trial, 28 percent of newly diagnosed patients with H3 K27M-mutant diffuse glioma responded to treatment with dordaviprone.
FierceBiotech4d
Septerna drops lead asset over bilirubin side effects 4 months after going public
Septerna stood out from the crowd of biotech IPOs last year due to the lack of clinical data to hand. Now, the data are ...
Merus N.V.: Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma
This marks the second BTD for petosemtamab in HNSCCUTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 18, 2025(Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length mult ...
manilatimes4d
Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma
BTD designation follows the initial receipt of BTD and Fast Track designation for petosemtamab for the treatment of patients with r/m HNSCC whose disease has progressed following treatment with ...